{
    "organizations": [],
    "uuid": "185e25e40273f6b5e7fdfc1daae05fcaa7d6be06",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kempharm-reports-q1-loss-per-share/brief-kempharm-reports-q1-loss-per-share-1-77-idUSASC0A1LD",
    "ord_in_thread": 0,
    "title": "BRIEF-KemPharm Reports Q1 Loss Per Share $1.77",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - KemPharm Inc:\n* KEMPHARM ANNOUNCES POSITIVE, TOPLINE RESULTS FROM AN INTRAVENOUS HUMAN ABUSE POTENTIAL TRIAL WITH KP415 PRODRUG; REPORTS Q1 2018 RESULTS\n* Q1 LOSS PER SHARE $1.77 * Q1 EARNINGS PER SHARE VIEW $-0.70 â€” THOMSON REUTERS I/B/E/S\n* NO STATISTICALLY SIGNIFICANT DIFFERENCE IN MEAN DRUG LIKING E(MAX) BETWEEN KP415 PRODRUG (57 POINTS) AND PLACEBO (54 POINTS)\n* KP415 PRODRUG DEMONSTRATED STATISTICALLY SIGNIFICANT DIFFERENCES COMPARED TO D-METHYLPHENIDATE HYDROCHLORIDE IN PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-11T04:50:00.000+03:00",
    "crawled": "2018-05-11T13:00:26.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "kempharm",
        "inc",
        "kempharm",
        "announces",
        "positive",
        "topline",
        "result",
        "intravenous",
        "human",
        "abuse",
        "potential",
        "trial",
        "kp415",
        "prodrug",
        "report",
        "q1",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "statistically",
        "significant",
        "difference",
        "mean",
        "drug",
        "liking",
        "e",
        "max",
        "kp415",
        "prodrug",
        "point",
        "placebo",
        "point",
        "kp415",
        "prodrug",
        "demonstrated",
        "statistically",
        "significant",
        "difference",
        "compared",
        "hydrochloride",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}